ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Results of Operations and Financial Condition

ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions.

Story continues below

On August10, 2017, Zosano Pharma Corporation (the “Company”) issued a press released titled “Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update.” The press release is furnished herewith as Exhibit 99.1

Item 2.02 Financial Statements and Exhibits.

Exhibit

Number

Exhibit Description

99.1 Press release dated August10, 2017, titled “Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update.”


Zosano Pharma Corp Exhibit
EX-99.1 2 d631900dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update     •   John Walker appointed permanent CEO at Zosano FREMONT,…
To view the full exhibit click here

About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

An ad to help with our costs